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Abstract
Background and Aims: Cycloxygenase-2 (COX-2) catalyses the rate limiting step of prostaglandin biosynthesis.
Despite previous studies, it is still unclear whether COX-2 is beneficial or detrimental to cardiovascular risk. The aim
of this study was to examine the -765G>C (rs20417) PTGS2 promoter gene variant, which encodes COX-2, in
relation to markers of cardiovascular risk in a sample of well-characterised subjects with diabetes mellitus.
Methods and Results: We observed that the CC genotype was more prevalent in Type 2 diabetes mellitus
compared to Type 1 (84.2 vs 15.8%; p ≤ 0.05), and was significantly associated with clinically manifest angina (GG
vs GC vs CC: 14.3% vs 15.6% vs 28.0%; p=0.009) and lower HDL-cholesterol levels (GG vs GC vs CC: 1.3 mmol/L
vs 1.4 mmol/L vs 1.2 mmol/L; p=0.032). This is in line with previous studies showing that -765G>C genotype variant
alters Sp1 binding, resulting in decreased COX-2 activity which is associated with atherosclerosis.
Conclusion: We conclude that the CC genotype may contribute to a reduction of prostaglandin E2 mediated
insulin secretion, predisposing those individuals to Type 2 diabetes mellitus. Further prospective work is warranted in
order to examine the association between COX-2 and cardiovascular risk.
Keywords: COX-2; Polymorphism; Type 2 diabetes; HDL; Angina;
Cardiovascular
Introduction
Cyclooxygenase exists in three isoforms, COX-1 which is
constitutively expressed across all tissues; COX-2 whose expression is
induced by a number of physiological stimuli and COX-3 a splice
variant of COX-1, commonly called COX-1b. Both COX-1 and COX-2
catalyse the rate limiting reaction in the synthesis of prostaglandins,
prostacyclins and thromboxanes, with COX-2, the inducible isoform,
favouring the production of lipid mediators in a cell specific manner
[1]. Prostaglandins and prostacyclins are mediators of inflammation
and also play a regulatory role in cardiovascular homeostasis. COX-2 is
of interest from a pharmacological perspective since non-steroidal
anti-inflammatory drugs (NSAIDs), including aspirin, are routinely
used in the prevention of cardiovascular disease and to alleviate pain
associated with inflammatory conditions [2].
COX-2 is involved in the pathogenesis of inflammatory conditions
including Type 2 diabetes mellitus [3] and atherogenesis [4]. Glucose
mediated increases in COX-2 expression result in reduced bio-
availability of the vasodilator nitric oxide and subsequent endothelial
dysfunction [5,6]. Nitric oxide has an additional cardio protective role
preventing the oxidation of low density lipoproteins (LDL). In the
absence of nitric oxide, LDL becomes oxidised, resulting in endothelial
dysfunction and subsequent higher atherosclerotic risk [6].
Additionally, the expression of COX-2 is up-regulated in macrophage,
endothelial and smooth muscle cells contained in atherosclerotic
lesions [7]. Increased production of prostaglandins in these lesions
contributes to plaque rupture and subsequent thrombosis which leads
to stroke or an acute coronary syndrome [8].
Studies have shown that COX-2 inhibition may improve endothelial
function [9] and hence have benefits on cardiovascular function.
Conversely, both prostaglandin E2 and prostacyclin synthesis are
thought to have an adaptive role in the reduction of high blood
pressure in patients with diabetes through increased COX-2 expression
resulting in vasodilation [10], as well as playing a cardio protective role
[11]. COX-2 also contributes to insulin signalling, as prostaglandin E2
in pancreatic β-cells has a negative effect on insulin secretion [12,13].
It is clear that COX-2 regulates a number of key pathways producing
paracrine hormones with a range of physiological functions and has
the potential to be a therapeutic to prevent cardiovascular disease [14].
The rs20417 (-765G>C) polymorphism lies in the promoter region
of the COX-2 gene and results in a G to C transfer at position -765
[15]. The G allele is associated with more efficient binding of Sp1 and
NF-κB transcription factors, increasing transcription of COX-2 [16].
The CC genotype has been shown to be associated with increased Type
2 diabetes mellitus prevalence of risk [17].
The aim of the pilot study was to investigate the association between
the rs20417 COX-2 polymorphism and coronary heart disease (CHD),
and selected relevant cardiovascular risk factors, including HDL-
cholesterol and LDL-cholesterol levels and LDL-particle size and
oxidised LDL (OxLDL) and total antioxidant status (TAOS) in a cross
sectional sample of patients with Type 1 and Type 2 diabetes mellitus.
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Methods
Samples
Patients were recruited from the University College London
Diabetes and Cardiovascular Study (UDACS), which has been
previously described [18]. Briefly, the pilot sample consists of 1011
consecutive subjects (Caucasian v Non-Caucasian v Unknown: 77.1 v
20.6 v 2.3% [Non-Caucasian includes Indian-Asian v Black v Asian
ethnicities: 53.8 v 37.5 v 8.7%]) recruited from the diabetes clinic at
University College London Hospitals NHS trust between the years
2001-2002. All patients had diabetes diagnosed by the WHO criteria
[19]. At the time of study recruitment (2001), the presence of CHD was
recorded if any patient had positive coronary angiography/angioplasty,
coronary artery bypass, cardiac thallium scan, exercise tolerance test,
myocardial infarction or symptomatic/treated angina. Any individual
who was asymptomatic or had negative investigations was categorised
as ‘no CHD’. Microalbuminuria was defined as an albumin:creatinine
ratio (ACR) of greater than 2.5 mg/mmol in men and 3.5 mg/mmol in
women [20] and ACR>30 mg/mmol. Plasma samples were collected
within a twelve month period and stored immediately at -80ºC. None
of the samples were fasting at the time of collection. Baseline
biochemical measurements (total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides) were performed within the local hospital
accredited chemical pathology laboratory. All experimental protocols
and the process for obtaining informed consent were approved by the
appropriate institutional review committee [18].
Genotyping of the rs20417 polymorphism
Genomic DNA was extracted from 5 ml EDTA blood samples.
Genotyping was conducted using polymerase chain reaction
amplification followed by restriction digest with Aci I. Primer
sequences were: forward GGCTGTATATCTGCTCTATATGC and
reverse CCGCTTCCTTTGTCCATCAG [21]. Genotype was
confirmed by two independent technicians and any discrepancy
resolved by repeat genotyping.
Measurement of plasma total anti-oxidant status
Plasma total anti-oxidant status (TAOS) was measured by Sampson’s
modification of Laight’s photometric microassay [22], using 2.5 μl
citrated plasma samples in 96-well ELISA plates. The TAOS of plasma
was determined by its capacity to inhibit the peroxidase-mediated
formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid
(ABTS+) radical. Previously, we have shown that baseline plasma
TAOS is associated with prospective risk and has a good correlation
with plasma F2-isoprostanes [23].
Measurement of plasma Ox-LDL
Plasma oxidized LDL (Ox-LDL) was measured using a
commercially available Enzyme-Linked Immunosorbent Assay
(ELISA) kit supplied by Mercodia (Uppsala, Sweden). In this assay a
monoclonal antibody is directed against antigenic determinants in the
Ox-LDL molecule (mAB-4E6).
Measurement of low density lipoprotein particle diameter
Low density lipoprotein (LDL) at d 1.019-1.063 g/ml was isolated
from EDTA plasma. Electrophoresis was performed as previously
described [24]. Polyacrylamide gels were used to determine LDL peak
particle diameter (LDL-PPD) and LDL mean particle diameter (LDL-
MPD) and the SD-LDL% was determined from the LDL particle size
[25].
Statistical analyses
Statistical analyses were performed using SPSS (version 19.0, SPSS
Inc., Chicago). Results are presented as mean and standard deviation.
Deviations from Hardy-Weinberg equilibrium were considered using
chi-squared tests. Allele frequencies are shown with the 95%
confidence interval. For data that was normally distributed after log
transformation, the geometric mean and approximate standard
deviation is shown. Analysis of variance (ANOVA) was used to assess
the association between genotype and baseline characteristics for data
that was normally distributed after log transformation. For data that
could not be transformed to a normal distribution the median and
interquartile range are shown, data was analysed by the Kruskal-Wallis
test and Mann-Whitney tests. Chi-squared tests were used to compare
differences in categorical variables by genotype. In all cases a p-value of
less than 0.05 was considered statistically significant. Two-sided
statistical testing was performed.
Results
Genotype data was available for all subjects. The distribution of
genotypes across the sample was not in Hardy-Weinberg equilibrium
(GG v GC v CC: 606 v 328 v 77, Χ2= 11.47, p<0.01) with a C allele
(rare allele) frequency of 0.24 [0.22-0.26]. There was no difference in
ethnic group (Caucasian%) by genotype (GG v GC v CC: 77.7% v
77.7% v 68.8%, p=0.299). A significant proportion of subjects with the
CC genotype were seen to have Type 2 diabetes mellitus (GG v GC v
CC: 79.5% v 77.2% v 84.2%, p=0.048), with the rare (C) allele
frequency of 0.24 for Type 2 diabetes mellitus.
Comparisons between genotypes showed that subjects with the CC
genotype had significantly lower levels of HDL-cholesterol (p=0.032), a
non-significant borderline association with the presence of CHD (GG
v GC v CC: 19.4% v 19.0% v 30.7%, p=0.06) and a significantly higher
prevalence of angina (p=0.009) (Table 1), which was still significant
after correction for age, sex, diabetes type and HDL-cholesterol (OR
0.43, 95%CI 0.24-0.79). However, genotype was not associated with
biochemical markers of oxidative stress including TAOS, OxLDL,
OxLDL:LDL or LDL particle size.
Further analysis of combined genotypes showed that the significant
prevalence of both CHD and angina was strongest in subjects who
were homozygous for the C allele (p=0.024 and p=0.005 respectively)
(Table 2), with angina conferring a 2.3 fold increased risk for those
carrying two C alleles, and remaining significant after correction for
age, sex and CHD (OR 2.26, 95%CI 1.32-3.87).
Discussion
We observed that the CC genotype of the COX-2 -765G>C
polymorphism was positively associated with a higher prevalence of
Type 2 diabetes mellitus and angina, as well as being associated with
lower levels of HDL-cholesterol. HDL-cholesterol has anti-atherogenic,
antiflammatory and antioxidant properties [26] and has been
associated with the up-regulation of COX-2 expression and
prostacyclin synthesis in endothelial cells [27]. Importantly, HDL-
cholesterol plays a role in reverse cholesterol transport from peripheral
tissues which are affected by the formation of atherosclerotic plaques.
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The efflux of HDL-cholesterol from the macrophage ‘foam’ cells to the
liver reduces the amount of cholesterol in the plaque via the cholesterol
excretion in bile and faeces [28]. The higher prevalence of CHD and
angina seen in the CC genotype may be due to reduced HDL-
cholesterol levels, since HDL-cholesterol is effective in countering the
formation of these diseases by increasing COX-2 expression within
smooth muscle [28,29]. The HDL-cholesterol induced COX-2
expression is directed towards prostacyclin production, a potent
vasodilator [29]. Therefore, low HDL-cholesterol levels result in a
lower COX-2 expression in the CC genotype which may lead to
increased blood pressure and subsequent coronary heart disease
manifesting in angina, however this would be more likely be expected
of the GG genotype, since endothelial dysfunction is increased with
COX-2 activity [5,9].
Prostaglandin E2 is synthesised from prostaglandin H2, the product
of the rate limiting reaction catalysed by COX-2 [1], therefore subjects
with the CC genotype may not have the capacity to produce
prostaglandin E2 at the rate required for the effective negative
modulation of insulin secretion in β-cells [12,13].
Measurement Type 1 Type 2 Other1 P-value
 (n=176) (n=783) (n=52)  
Age (yrs)# 48.6 [39-57] 66.1 [58-73] 57.2 [50-62] <0.001
Males % (n) 62.4 (108) 62.1 (484) 74.2 (23) 0.391
Caucasian % (n) 94.9 (167) 75.0 (587) 48.1 (25) <0.001
Duration (yrs)# 24.0 [14-33] 9.0 [4-16] 8.0 [3-16] <0.001
Weight (kg)* 74.9 (5.6) 79.4 (7.1) 75.0 (8.3) <0.001
BMI (kg/m2)* 26.1 (1.9) 28.8 (2.3) 25.8 (2.8) <0.001
SBP (mmHg)# 132 [122-142] 139 [128-152] 135 [127-142] <0.001
DBP (mmHg)# 79 [73-85] 80 [73-87] 85 [75-91] 0.039
Cholesterol (mmol/L)* 5.2 (0.4) 4.9 (0.5) 4.9 (0.6) 0.029
LDL-C (mmol/L)# 2.9 [2.3-3.5] 2.7 [2.1-3.3] 2.6 [2.0-3.4] 0.101
HDL-C (mmol/L)# 1.7 [1.4-2.1] 1.2 [1.0-1.5] 1.2 [1.1-1.4] <0.001
Triglyceride (mmol/L)* 1.1 (0.3) 1.9 (0.5) 1.7 (0.4) <0.001
HbA1c (%)* 8.1 (0.6) 7.8 (0.7) 8.4 (0.7) 0.021
HbA1c (mmol/mol)* 64 (6.7) 61 (7.9) 68 (7.7) 0.014
Glucose (mmol/L)* 9.0 (2.5) 9.9 (1.9) 10.6 (2.6) 0.04
ACR# 1.2 [0.0-2.9] 2.6 [1.2-7.4] 1.2 [0.0-3.4] <0.001
CHD % (n) 4.0 (7) 24.3 (189) 6.5 (2) <0.001
Angina % (n) 2.9 (5) 19.2 (149) 3.2 (1) <0.001
Mean and standard deviation shown for normally distributed data. *Log transformed data shown by geometric mean and approximate standard deviation (analysis
performed by ANOVA). #Median and interquartile range shown for data that was not normally distributed even after log transformation (analysis performed by Kruskal-
Wallis). Categorical data was analyzed using chi- squared. 1Other includes pancreatic diabetes and cases with no recorded diabetes status.
Table 1: Baseline characteristics by diabetes type.
Excessive insulin signalling is thought to contribute to the
development of insulin resistance in Type 2 diabetes mellitus [30].
Circulating insulin and prostaglandin E2 were not recorded in this
study, however this relationship may explain the association between
patients with the CC genotype and Type 2 diabetes mellitus.
Prostaglandin E2 prevents pancreatic islet β-cell dysfunction caused by
interleukin-1β, therefore in the absence of COX-2 expression,
interleukin-1β which is pro-inflammatory can cause β-cell dysfunction
leading to the inflammation driven development of Type 2 diabetes
mellitus. This model agrees with many pieces of data concerning
inflammation as a causative factor in the pathogenesis of diabetes.
In summary, we observed a higher prevalence of Type 2 diabetes
mellitus in those with the CC genotype, possibly as a result of a limited
production of prostaglandin E2. Additionally, there was a significant
association with an increased incidence of angina and a borderline
association with coronary heart disease. Higher HDL-cholesterol levels
have been reported to be preventative in diseases related to the
formation of atherosclerotic plaques [28], this is supported by the
significantly lower levels of HDL-cholesterol combined with higher
incidences of angina and CHD seen in our CC genotype subjects.
However, no COX-2 mediated changes in HDL-cholesterol have been
described in the literature. Researching the possibility of COX-2
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mediated changes in HDL-cholesterol or other lipoproteins may help
elucidate the over physiological role of COX-2 and maybe aid in
identifying drug targets to aid in the prevention of atherosclerosis.
 
GG GC CC
P
GG/GC CC
P
GG GC/CC
P
(n=606) (n=328) (n=77) (n=934) (n=77) (n=606) (n=405)
HDL-C
(mmol/L)#
1.3 1.4 1.2
0.032
1.3 1.2
0.253
1.3 1.4
0.068
[1.1-1.6] [1.1-1.6] [1.1-1.5] [1.1-1.6] [1.1-1.5] [1.1-1.6] [1.1-1.6]
TAOS (%)#
43.6 45.3 42.3
0.312
44.3 42.3
0.217
43.6 44.9
0.689
[35-51] [36-51] [30-53] [35-51] [30-53] [35-51] [35-52]
OxLDL (U/L)#
45.6 47 48.6
0.288
45.9 48.6
0.128
45.6 47.2
0.356
[40-55] [35-58] [40-61] [35-55] [40-61] [40-55] [36-58]
Mean LDL size
(nm) 26.8 (0.9) 26.8 (0.9) 27.0 (1.0) 0.424 26.8 (0.9) 27.0 (1.0) 0.195 26.8 (0.9) 26.8 (0.9) 520
Peak LDL size
(nm) 26.6 (1.0) 26.7 (1.0) 26.6 (1.1) 0.897 26.6 (1.0) 26.6 (1.1) 0.911 26.6 (1.0) 26.7 (1.0) 0.643
T2DM % (n) 79.5 (469) 77.2 (250) 84.2 (64) 0.048 78.7 (719) 84.2 (64) 0.439 79.5 (469) 78.5 (314) 0.022
CHD % (n) 19.4 (114) 19.0 (61) 30.7 (23) 0.06 19.3 (175) 30.7 (23) 0.024 19.4 (114) 21.2 (84) 0.517
Angina % (n) 14.3 (84) 15.6 (50) 28.0 (21) 0.009 14.8 (134) 28.0 (21) 0.005 14.3 (84) 17.9 (71) 0.13
Mean and standard deviation shown for normally distributed data. #Median and interquartile range shown for data that was not normally distributed even after log
transformation. Analysis performed by ANOVA for normally distributed data and by Kruskal-Wallis non-normally distributed data. χ2-test was used to compare groups.
P-values<0.05 are considered to be statistically significant and are in bold.
Table 2: Baseline differences by combined -765G>C promoter variant.
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